Clinical trial

Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

NCT06236997

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Adebrelimab Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Radiation Therapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention etoposide, carboplatin(EC) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2024-02-10

PhasePHASE2

Conditions

Small Cell Lung Carcinomaverified · MONDO: small cell lung carcinoma

Interventions

AdebrelimabDRUG

Radiation TherapyRADIATION

etoposide, carboplatin(EC)DRUG

Sponsors & collaborators

Henan Cancer Hospitallead sponsor

Huazhong University of Science and Technologycollaborator

Mapped research locations

WuhanHubei, China1 ZhengzhouHenan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06236997 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.